Laddar...
Fulvestrant reverses doxorubicin resistance in multidrug-resistant breast cell lines independent of estrogen receptor expression
Drug resistance, a major obstacle to successful cancer chemotherapy, frequently occurs in recurrent or metastatic breast cancer and results in poor clinical response. Fulvestrant is a new type of selective estrogen receptor (ER) downregulator and a promising endocrine therapy for breast cancer. In t...
Sparad:
| I publikationen: | Oncol Rep |
|---|---|
| Huvudupphovsmän: | , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
D.A. Spandidos
2017
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5355712/ https://ncbi.nlm.nih.gov/pubmed/28000875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2016.5315 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|